UK-1745

• Description:

  UK-1745 is a cardiotonic agent with vasodilating and antiarrhythmic properties. It increases intracellular levels of cyclic adenosine monophosphate (cAMP) in cardiomyocytes by inhibiting phosphodiesterase III, thereby enhancing myocardial contractility. Additionally, UK-1745 exhibits β-adrenergic receptor blocking activity, which helps reduce the oxygen consumption of the heart and prevent calcium overload. These characteristics make UK-1745 a promising candidate for research in congestive heart failure[1][2].

• UNSPSC:

  12352005

• Target:

  Adrenergic Receptor; Phosphodiesterase (PDE)

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/uk-1745.html

• Smiles:

  CC1(C2=C(NC1=O)C(C)=CC3=C2O[C@](CN)(C)[C@H]3C)C.Cl

• Molecular Formula:

  C16H23ClN2O2

• Molecular Weight:

  310.82

• References & Citations:

  [1]Sawada, et al. "Pharmacological Characterization of Effects of UK-1745, a Novel Cardiotonic Agent withβ-Adrenoceptor-blocking Action, in Aequorin-loaded Canine Right Ventricular Muscle." Journal of molecular and cellular cardiology 31.5 (1999) : 1047-1062.|[2]Uchida, et al. "Cardiovascular effects of (2RS, 3SR) -2-aminomethyl-2, 3, 7, 8-tetrahydro-2, 3, 5, 8, 8-pentamethyl-6H-furo-[2, 3-e] indol-7-one hydrochloride (UK-1745), a novel cardiotonic agent with vasodilatory and antiarrhythmic properties." Arzneimittel-forschung 48.3 (1998) : 219-231.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [170684-14-7]